Facebook

Twitter

Linkedin

Pinterest

Email

Clinical Trials Search

Clinical Trial 21712

Cancer Type: Gastrointestinal Tumor
Study Type: Treatment
NCT#: NCT05153772

Phase: Phase II
Principal Investigator: Strosberg, Jonathan

Call 813-745-6100
or 1-800-679-0775 Learn More

Overview

Study Title

A Phase 2 Open Label Study to Evaluate the Safety and Effectiveness of 212Pb-DOTAMTATE in PRRT Naïve Subjects with Somatostatin Receptor Expressing Neuroendocrine Tumors

Summary

This is a phase 2 study of 212Pb-DOTAMTATE enrolling adult patients with positive somatostatin positive neuroendocrine tumors with no prior history of peptide receptor radionuclide therapy (PRRT naive).

Objective

The primary objectives of the study are: To evaluate the efficacy of the Recommended Phase 2 Dose (RP2D) of 212Pb-DOTAMTATE through overall response rate (ORR) complete plus partial responses per RECIST 1.1: and To assess the safety and tolerability of 212Pb-DOTAMTATE used for targeted alpha emitter therapy of peptide receptor radionuclide therapy (PRRT); and Secondary Objectives The secondary objectives of the study are: To determine median Progression free survival (mPFS); To determine the Overall Survival (OS); To determine the Time to Tumor Progression (TTP); and To evaluate the health-related quality of life (HRQL), relative to baseline.

Treatments

Therapies

Radiotherapy

Medications

Pb-DOTAMTATE ()

Inclusion Criteria

Inclusion Criteria:

Male or female 18 years of age or older with unresectable or metastatic histologically confirmed NET

All subjects must have received and progressed following somatostatin analog administration

For PRRT naive patients, documented progression of disease following previous therapy within 12 months prior to enrollment and the presence of at least 1 site of measurable disease per RECIST 1.1;

3.5.Subjects who previously received PRRT must have documented progression of disease and at least 1 site of measurable disease per RECIST 1.1 after receiving up to 4 doses (≤ 880 mCi) of 177Lu-DOTATATE/DOTATOC and received their last dose at least 6 months prior to Day 1.

Confirmed presence of somatostatin receptors on all lesions including the non-target and measurable lesions documented by CT/MRI scans, based on positive 68Ga-DOTATATE (NETSPOT®), 64Cu-DOTATATE, or other FDA approved SSTR PET/CT imaging within 6 weeks prior to enrollment. Follow up imaging should be performed with the same agent or modality used at baseline; (1) Target lesions must be positive (greater than grade 2 uptake Krenning Score) or must have an SUV of more than the normal liver background. (2)Lytic bone lesions, with an identifiable soft tissue component, evaluated by CT or MRI, can also be considered measurable lesions if the soft tissue component otherwise meets the definition of measurability according to RECIST 1.1. In any case, osteoblastic bone lesions are not measurable.

Eastern Cooperative Oncology Group (ECOG) status 0-2;

Life expectancy of at least 12 weeks in the opinion of the investigator at the time of screening;

Sufficient bone marrow capacity and organ function in the recent blood tests within 3 weeks prior to Day 1, as defined in protocol.

Be willing to practice the following medically acceptable methods of birth control (both women of childbearing potential (WOCBP) and men who have partners of childbearing potential) from the Screening Visit through 3 months after the final administration 212Pb-DOTAMTATE

Other criteria may apply

Exclusion Criteria

Exclusion Criteria:

For PRRT naive patients, prior whole-body radiotherapy or PRRT using 177Lu/90Y/111In-DOTATATE/ DOTATOC or TAT.

For subjects who previously received PRRT: a. Prior treatment with Y-DOTATATE/DOTATOC; b. Prior treatment with Ac-DOTATATE/DOTATOC; c. Prior treatment with In-DOTATATE/DOTATOC

Prior regional hepatic radionuclide therapy within 4 months prior to enrollment or prior nonradioactive regional hepatic therapy within 6 months prior to enrollment.

Known hypersensitivity to somatostatin analogues, AA infusion, or 212Pb-DOTAMTATE;

Therapeutic use of any somatostatin analogue, including Sandostatin® LAR (within 28 days) and Sandostatin® (within 1 day) prior to Cycle 1 Day;

History of myelodysplastic syndrome (MDS);

Female patients who are pregnant or lactating;

Indication for surgical lesion removal with curative potential;

Known brain metastases, unless these metastases have been treated and/or stable for 6 months prior to enrollment;

Experimental cancer treatments or other investigational therapies within 6 weeks or five half-lives of the investigational medication prior to Day 1;

Uncontrolled congestive heart failure (NYHA II, III, IV);

Uncontrolled diabetes mellitus as defined by a hemoglobin A1C >10.0;

Evidence of renal obstruction based on Tc-99m DTPA or TER for MAG3 renal scintigraphy or renal ultrasound.

Known or active human immunodeficiency virus (HIV) or hepatitis B or C virus unless cured;

Known or suspected active drug or alcohol abuse;

Participation in other interventional clinical studies within 30 days prior to Day 1;

Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and proven no evidence of recurrence for 5 years;

Any somatic or psychiatric disease/condition or abnormal laboratory test that in the opinion of the investigator, may interfere with the objectives and assessments of the study; or

Unable to comply with the requirements of the study protocol or be unsuitable for the study for any reason, in the opinion of the investigator.

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.